07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

Merck KGaA, Aeterna Zentaris deal

Merck’s EMD Serono unit granted Aeterna Zentaris rights to co-promote Saizen in the U.S. Aeterna Zentaris will be responsible for detailing Saizen to designated medical professionals through its own networks and through a subcontracting agreement...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

Ascend Therapeutics, Aeterna Zentaris deal

Aeterna Zentaris and Ascend will co-promote Ascend's EstroGel transdermal estrogen gel and Aeterna Zentaris' Macrilen macimorelin acetate ( AEZS-130 ) in the U.S., starting next quarter. Each partner is entitled to commissions on net sales...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Zogenix sales and marketing update

Valeant granted Zogenix co-promotion rights in the U.S. to migraine drug Migranal dihydroergotamine. Beginning in late July, Zogenix's sales force will start promoting Migranal to its customer base of prescribers, which is primarily composed of...
07:00 , May 5, 2008 |  BC Week In Review  |  Clinical News

EstroGel estradiol regulatory update

FDA approved a boxed warning to the label of EstroGel estradiol to warn that estrogens with or without progestins should not be used to prevent cardiovascular disease nor dementia. The transdermal estrogen gel is approved...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

Ascend, Valeant sales and marketing update

VRX granted Ascend exclusive rights to market Migranal dihydroergotamine nasal spray to OB/GYNs in the U.S. to treat migraine headaches. VRX will continue to market the drug to physicians outside the OB/GYN specialty area. VRX...
07:00 , May 15, 2006 |  BC Week In Review  |  Company News

Critical Therapeutics management update

Critical Therapeutics Inc. (CRTX), Lexington, Mass.   Business: Inflammation, Dermatology, Pulmonary   Hired: Dana Hilt as SVP of clinical development and CMO, formerly SVP and CMO at Ascend Therapeutics Inc.  ...
08:00 , Jan 3, 2005 |  BC Week In Review  |  Company News

Ascend management update

Ascend Therapeutics Inc. , Herndon, Va.   Business: Drug delivery   Hired: Thomas MacAllister as SVP and general counsel, formerly COO at Sucampo Pharmaceuticals Inc.  ...
08:00 , Dec 20, 2004 |  BC Week In Review  |  Company News

Ascend Therapeutics management update

Ascend Therapeutics Inc. , Herndon, Va.   Business: Drug delivery, Neurology   Hired: Thomas MacAllister as SVP and general counsel; formerly COO and general counsel at Sucampo Pharmaceuticals Inc.  ...
08:00 , Dec 13, 2004 |  BC Week In Review  |  Clinical News

4-OHT gel: Preliminary Phase II data

Preliminary data from a dose-ranging, double-blind, placebo-controlled, U.S. and European Phase II trial in 130 premenopausal women showed that transdermal administration of a 4mg dose of 4-OHT gel to the breast yielded a statistically significant...
07:00 , Jul 12, 2004 |  BC Week In Review  |  Company News

Ascend, Besins International Holdings deal

Ascend received exclusive North American rights to Besins' Andrin transdermal dihydrotestosterone gel, which is in Phase II testing to treat late onset hypogonadism. Under a February deal, Ascend received similar rights to Besins' TamoGel 4-hydroxytamoxifen...